ARMP stock forecast, quote, news & analysis
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology... Show more
Why Armata Pharmaceuticals (ARMP) Stock Is Down -28% in the Last 30 Days
Key Takeaways
- Armata Pharmaceuticals shares have fallen roughly 28% over the past 30 days, sliding from about $4.26 to near $3.05.
- The decline has pushed the stock toward the lower end of its 52-week range, which spans a high of $16.34 and a low of $2.75.
- Balance-sheet strain remains the dominant concern: limited cash, elevated debt, negative equity, and ongoing dilution risk are weighing on sentiment.
- Positive clinical and funding news, including FDA Breakthrough Therapy designation for AP-SA02, has not yet reversed the downtrend.
- Wall Street coverage remains limited but constructive, with two analysts maintaining buy ratings and an average price target well above current levels.
Armata Pharmaceuticals (ARMP) Company Overview and Market Position
Armata Pharmaceuticals is a late clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Bacteriophages, or "phages," are naturally occurring viruses that selectively target and destroy specific bacteria, offering a potential alternative to broad-spectrum antibiotics.
The company's lead candidate, AP-SA02, is a fixed multi-phage cocktail being developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia (SAB) caused by either methicillin-sensitive or methicillin-resistant strains. AP-SA02 has received FDA Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product designations. Armata also advances AP-PA02, targeting Pseudomonas aeruginosa infections in patients with cystic fibrosis. The company operates its own in-house cGMP manufacturing facility in Los Angeles, a competitive advantage in a niche where manufacturing capability is a key differentiator.
Armata Pharmaceuticals (ARMP) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ARMP shares have declined approximately 28%, moving from a closing price around $4.26 to roughly $3.05. The stock touched a 52-week low of $2.75 during this stretch before recovering modestly, underscoring the volatility that has characterized the name.
The quarterly picture is similarly weak. Over the past three months, the stock has fallen roughly 37%, continuing a longer slide from its 52-week high of $16.34. ARMP now trades below both its 50-day moving average near $4.38 and its 200-day moving average near $7.14, indicating persistent downward momentum across short- and intermediate-term timeframes.
What Drove ARMP Stock Price in the Last 30 Days
The most significant headwind over the past month has been capital-structure and liquidity pressure rather than clinical setbacks. Armata reported cash and cash equivalents of approximately $24 million as of June 30, 2026, against total debt of roughly $314 million. The company carries negative shareholder equity, a current ratio of about 0.11, and has disclosed substantial doubt about its ability to continue as a going concern without additional financing.
Dilution overhang has compounded the selling pressure. The company maintains an at-the-market (ATM) offering program and a shelf registration, and it has outstanding warrants representing a meaningful portion of shares outstanding. Convertible debt and persistent negative free cash flow reinforce investor concerns that further equity issuance may be needed to fund the planned Phase 3 program.
Notably, the decline occurred despite a series of constructive announcements. In September 2026, Armata received FDA Breakthrough Therapy designation for AP-SA02 and disclosed an additional $3.7 million in non-dilutive funding from the U.S. Department of War, bringing cumulative support under the award to roughly $32.4 million. Broader weakness across small- and mid-cap biotech names also contributed to the pressure.
What Drove ARMP Stock Performance Over the Last Quarter
The quarterly decline reflects a longer-running repricing of risk. After a sharp run-up that lifted the stock to a 52-week high in late 2025, investor focus shifted from the promise of Armata's phage platform to the durability of its balance sheet. A heavy reliance on majority shareholder and lender Innoviva (INVA), which holds roughly 69% of outstanding shares plus warrants, has concentrated both financing power and equity ownership in a single party.
At the same time, the company advanced toward a pivotal Phase 3 superiority study for AP-SA02, submitting its Phase 3 protocol and completing manufacturing engineering runs. While these milestones de-risked the clinical path, the market has largely emphasized the cost of executing a late-stage trial and the financing uncertainty that comes with it.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's artificial-intelligence-driven trading bots. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers across the market, but only the top-performing and most relevant bots are surfaced in this featured section. Each bot operates with its own strategy, timeframe, and performance metrics, so investors can evaluate approaches ranging from short-term tactical trading to longer-horizon trend following. For traders seeking data-driven signals and automated market analysis, exploring the Trending AI Robots section can be a practical way to discover tools aligned with specific investing styles.
ARMP Stock Forecast Drivers: What Investors Should Watch Next
Investors following ARMP should monitor several key factors in the months ahead. The initiation of the planned Phase 3 superiority study for AP-SA02 remains the central clinical catalyst, with trial execution, patient enrollment, and interim data readouts likely to drive sentiment. Continued non-dilutive federal funding commitments and any additional financing arrangements will be critical, given the company's going-concern disclosure and thin cash position.
Upcoming earnings reports and guidance updates will provide clarity on operating expenses, cash runway, and dilution plans. Regulatory interactions with the FDA, manufacturing scale-up at the company's cGMP facility, and any partnership or strategic developments involving Innoviva (INVA) also warrant attention. Macroeconomic conditions affecting small-cap biotech financing, including interest rates and investor appetite for pre-revenue clinical-stage companies, will continue to shape the broader trading environment. As with all clinical-stage biotechs, outcomes carry meaningful risk, and no single catalyst should be viewed in isolation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARMP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ARMP turned positive on October 20, 2026. Looking at past instances where ARMP's MACD turned positive, the stock continued to rise in 44 of 47 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARMP's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 66 cases where ARMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +21.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARMP advanced for three days, in 217 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ARMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARMP as a result. In 93 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 10-day moving average for ARMP crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ARMP entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.555) is normal, around the industry mean (2.973). P/E Ratio (-0.652) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ARMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel bacteriophage-based therapeutics
Industry Biotechnology